Stout performed common stock valuations for Capstan Therapeutics, a biotechnology company, to comply with IRC 409A and ASC 718 regulations. Capstan has attracted significant attention from Big Pharma, with investment from Eli Lilly, Pfizer Ventures, Leaps by Bayer, Novartis Venture Fund, and Bristol Myers Squibb.

Our team plans to support Capstan throughout its growth, offering valuation and financial reporting assistance as the company advances.